The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion

P De Cicco, G Ercolano, A Ianaro - Frontiers in immunology, 2020 - frontiersin.org
Suppression of antitumor immune responses is one of the main mechanisms by which tumor
cells escape from destruction by the immune system. Myeloid-derived suppressor cells …

Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells

K Jin, C Qian, J Lin, B Liu - Frontiers in oncology, 2023 - frontiersin.org
Cyclooxygenases-2 (COX-2) and Prostaglandin E2 (PGE2), which are important in chronic
inflammatory diseases, can increase tumor incidence and promote tumor growth and …

[HTML][HTML] Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

A Cortellini, M Tucci, V Adamo, LS Stucci… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and
antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We …

Mechanisms and prevention of UV‐induced melanoma

A Sample, YY He - Photodermatology, photoimmunology & …, 2018 - Wiley Online Library
Melanoma is the deadliest form of skin cancer and its incidence is rising, creating a costly
and significant clinical problem. Exposure to ultraviolet (UV) radiation, namely UVA (315 …

[HTML][HTML] Intratumor and intertumor heterogeneity in melanoma

TM Grzywa, W Paskal, PK Włodarski - Translational oncology, 2017 - Elsevier
Melanoma is a cancer that exhibits one of the most aggressive and heterogeneous features.
The incidence rate escalates. A high number of clones harboring various mutations …

[HTML][HTML] Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line …

A Cortellini, M Di Maio, O Nigro, A Leonetti… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Some concomitant medications including antibiotics (ATB) have been
reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in …

Multispecific Platinum (IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX‐2 and PD‐L1

S Jin, N Muhammad, Y Sun, Y Tan, H Yuan… - Angewandte …, 2020 - Wiley Online Library
Breast cancer (BC) is one of the most common malignancies in women and often
accompanied by inflammatory processes. Cyclooxygenase‐2 (COX‐2) plays a vital role in …

[HTML][HTML] Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

H Deng, A Kan, N Lyu, M He, X Huang… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Neutrophils play a controversial role in tumor development. The function of
programmed cell death-1 ligand (PD-L1+) neutrophils, however, may inhibit the cytotoxicity …

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

E Hays, B Bonavida - Drug Resistance Updates, 2019 - Elsevier
Recent advances in the treatment of various cancers have resulted in the adaptation of
several novel immunotherapeutic strategies. Notably, the recent intervention through …

Ketoprofen and loxoprofen platinum (iv) complexes displaying antimetastatic activities by inducing DNA damage, inflammation suppression, and enhanced immune …

Z Li, Q Wang, L Li, Y Chen, J Cui, M Liu… - Journal of Medicinal …, 2021 - ACS Publications
Metastasis is a major contributor of death in cancer patients, and there is an urgent need for
effective treatments of metastatic malignancies. Herein, ketoprofen (KP) and loxoprofen (LP) …